Heart failure drug shows promise for Non-Diabetics
NCT ID NCT07112274
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This completed study tested whether empagliflozin, a diabetes drug, can improve heart structure and function in 50 non-diabetic patients with heart failure with preserved ejection fraction. Participants took either empagliflozin or a placebo daily. Researchers measured heart stress markers to see if the drug helps reduce cardiac remodeling.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
empagliflozin (10 mg tablet once daily)
What this could lead to
If successful, this could point toward a new treatment option for heart failure patients who are not diabetic, potentially improving heart function and quality of life.
What could go wrong
This is a small, completed trial with only 50 participants, so results may not apply to everyone. The study measured biomarkers, not long-term outcomes, so real-world benefits are uncertain.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEART FAILURE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Rehab Hussein Werida
Damanhūr, Elbehairah, 31527, Egypt